-
Product Insights
NewNet Present Value Model: Achilles Therapeutics Plc’s ATL-001
Empower your strategies with our Net Present Value Model: Achilles Therapeutics Plc's ATL-001 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-1102 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-1102 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-1102 in Duchenne Muscular Dystrophy Drug Details: ATL-1102, (TV-1102, ISIS 107248)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-001 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-001 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-001 in Metastatic Melanoma Drug Details: ATL-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATL-001 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATL-001 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATL-001 in Non-Small Cell Lung Cancer Drug Details: ATL-001 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Non-Small Cell Lung Cancer Drug Details: Tucidinostat...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Metastatic Melanoma Drug Details: Tucidinostat (Epidaza, Hiyasta) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tucidinostat in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tucidinostat in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tucidinostat in Anaplastic Large Cell Lymphoma (ALCL) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – KPG-818 in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KPG-818 in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KPG-818 in Systemic Lupus Erythematosus Drug Details: KPG-818 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – KPG-818 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KPG-818 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KPG-818 in Mantle Cell Lymphoma Drug Details: KPG-818 is under development...